Factory 99% Ondansetron Powder CAS 99614-02-5 Chemical Intermediate Antiemetic Ondansetron

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A635
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Ondansetron
• CAS: 99614-02-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Antiemetic
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Ondansetron
Appearance	White Powder
CAS NO.	99614-02-5
MF	C18H19N3O3
Storage	Keep in a cool, dry, dark location

 

Ondansetron is a potent and highly selective 5-HT3 receptor antagonist. It is primarily used in medical practice for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiation therapy, and surgical procedures. By blocking the 5-HT3 receptors in the brain, Ondansetron reduces the sensation of nausea and vomiting, thereby enhancing patient comfort and adherence to medical treatments.

 

1. Antiemetic Agent: Ondansetron is commonly used to prevent nausea and vomiting associated with various conditions, such as chemotherapy, radiation therapy, and postoperative recovery.
2. Gastrointestinal Disorders: It can also be prescribed to treat nausea and vomiting caused by gastrointestinal disorders or other medical conditions that may induce such symptoms.
3. Pediatric Use: Ondansetron is sometimes administered to children to manage nausea and vomiting related to surgical procedures, cancer treatments, or other medical interventions.

1. Selective Serotonin Receptor Antagonist: Ondansetron works by blocking the action of serotonin in the body, specifically at the 5-HT3 receptors located in the chemoreceptor trigger zone and the vomiting center of the brain. This action helps to prevent nausea and vomiting.
2. Central Nervous System Modulation: By inhibiting serotonin's effects on these receptors, ondansetron modulates the neural pathways responsible for initiating the vomiting reflex, thereby reducing the incidence and severity of nausea and vomiting.
3. Enhanced Patient Comfort: By effectively controlling nausea and vomiting, ondansetron enhances patient comfort and adherence to medical treatments, especially in scenarios where nausea and vomiting could significantly impact the quality of life and treatment outcomes, such as during chemotherapy.